Neuland Laboratories Share News - Latest Updates, Live News & More

Latest news about Neuland Laboratories

Neuland Laboratories Reports Record Q2 Revenue of Rs 516 Crore, Up 63.7% Year-on-Year 2 days ago

Neuland Laboratories achieved its highest ever quarterly revenue of Rs 516 crore in Q2, a 63.7% increase from the previous year. The growth was primarily driven by strong performance in the Contract Manufacturing Services (CMS) segment. EBITDA reached Rs 156.90 crore with a 30.4% margin, while Profit After Tax rose to Rs 96.50 crore from Rs 32.00 crore in Q2 last year. The company's CMS segment, now accounting for over half of revenues, showed continued strong growth. The Generic Drug Substances segment saw good contributions from products like Ezetimibe and Mirtazapine. Neuland's peptide facility investment is progressing as planned, with Module-1 expected to be operational next financial year. Despite optimism about growth, management cautioned about potential quarter-to-quarter unevenness in business performance.

Neuland Laboratories Posts Impressive Q2 Results with Nearly Tripled Net Profit 4 days ago

Neuland Laboratories Reports Stellar Q2 FY26 Performance with 195% Surge in Net Profit 7 days ago

Neuland Laboratories Shareholders Overwhelmingly Approve Leadership Re-designations 8 days ago

Neuland Laboratories Announces Q2 FY26 Earnings Call on November 7, 2025 Oct 28, 2025

More news about Neuland Laboratories

23Sept 25

Neuland Laboratories Announces Major Leadership Reshuffle for 2026

Neuland Laboratories Ltd has announced significant changes in its executive leadership, effective April 1, 2026. Mr. Sucheth Rao Davuluri will transition from Vice Chairman & CEO to Executive Vice Chairman, focusing on long-term planning and strategic initiatives. Mr. Saharsh Rao Davuluri will be re-designated from Vice Chairman & Managing Director to CEO & Managing Director, taking charge of day-to-day operations. The restructuring aims to balance short-term operational needs with long-term strategic goals, positioning Neuland for growth in the evolving pharmaceutical industry. The changes are subject to shareholder approval.

16Sept 25

Neuland Laboratories Achieves Remarkable Growth: 433% Yearly and 250% Monthly Surge

Neuland Laboratories Limited (NSE: NEULANDLAB) has reported remarkable growth figures. The pharmaceutical company announced a 433.00% increase year-on-year and a 250.00% growth on a monthly basis. These figures indicate substantial expansion in operations and financial performance, potentially reflecting broader positive trends in the pharmaceutical industry.

30Aug 25

Neuland Laboratories Expands Capacity: Commences Commercial Production at Unit 3 in Telangana

Neuland Laboratories has started commercial production at its expanded Unit 3 manufacturing facility in Telangana. The expansion, previously announced on November 10, 2023, is located in Gaddapotharam Village, Sangareddy District. This development is expected to enhance the company's production capabilities and strengthen its position in the pharmaceutical manufacturing sector. The company has informed stock exchanges about this milestone in compliance with SEBI regulations.

26Aug 25

Neuland Laboratories Seeks Shareholder Approval for Dr. Ravi Shankar Gopinath's Appointment as Independent Director

Neuland Laboratories has initiated a postal ballot to appoint Dr. Ravi Shankar Gopinath as an Independent Director for a five-year term from August 1, 2025, to July 31, 2030. Dr. Gopinath, 59, brings extensive experience in strategy, digital technologies, and operational excellence. The e-voting period is from August 28 to September 26, 2025, with results to be announced by September 28, 2025. The Board of Directors recommends the appointment, citing Dr. Gopinath's expertise as beneficial to the company.

04Aug 25

Neuland Laboratories Reports 32% Revenue Decline in Q1, Remains Optimistic for Strong Growth

Neuland Laboratories experienced a 32.4% decrease in Q1 revenue, with total income at Rs. 300.60 crores compared to Rs. 444.00 crores last year. The decline was attributed to uneven order flows in CDMO and specialty GDS business. Despite this, the company maintains a positive outlook for the full year, expecting commercialization of a new CMS molecule, commercial production from Unit 3, and growing interest in peptide capabilities. The company invested Rs. 79.00 crores in CAPEX during Q1 and reaffirmed its 3-5 year CAGR target of 20%.

31Jul 25

Neuland Labs Reports Q1 FY26 Results: Revenue Dips, Growth Plans Remain Intact

Neuland Laboratories Limited reported a 32.4% decrease in total income to ₹300.60 crore for Q1 FY26. EBITDA fell 67.3% to ₹42.10 crore, with margins contracting to 14%. Profit After Tax declined 86.1% to ₹13.70 crore. Despite weak quarterly performance, management remains confident about future growth, citing ongoing investments, anticipated growth in commercial molecules, and new business influx. The company's Custom Manufacturing Solutions segment saw growth, while Generic Drug Substances segment had key contributions from prime products. Neuland's Unit-2 received an Establishment Inspection Report following a successful FDA inspection.

31Jul 25

Neuland Laboratories Reports Q1 FY26 Results and Reappoints Independent Director

Neuland Laboratories announced Q1 FY26 financial results with revenue at ₹292.75 crore, down 33.4% YoY. Profit decreased to ₹13.71 crore from ₹98.34 crore in Q1 FY25. EBITDA margin fell to 14.00% from 28.90%. Despite lower results, management remains optimistic about future growth. The company reappointed Dr. Ravi Shankar Gopinath as an Independent Director for a five-year term, subject to shareholder approval.

23Jul 25

Neuland Laboratories Unveils Detailed Commission Structure for Executive Director's Reappointment

Neuland Laboratories has released an addendum to its 41st AGM notice, detailing the commission structure for Mr. Davuluri Saharsh Rao's reappointment. The performance-based structure caps the commission at 2% of net profits or INR 10 crores, whichever is lower. It employs a balanced scorecard approach with 60% weightage on financial parameters and 40% on non-financial metrics. A minimum 70% achievement against set goals is required for eligibility. The Board will determine the commission based on the Nomination and Remuneration Committee's recommendations.

14Jul 25

Neuland Laboratories Shares Surge 12% on Final Dividend Announcement

Neuland Laboratories' stock price increased by 12% to Rs 13,750.00 following the announcement of a final dividend of Rs 12.00 per share (120% of face value) for the fiscal year 2025. The record date for dividend eligibility is set for July 18, 2025. The stock is trading above all eight Simple Moving Averages, indicating strong upward momentum.

17Jun 25

SEBI Issues Administrative Warning to Neuland Laboratories Over Insider Trading Violation

Neuland Laboratories has been issued an administrative warning by SEBI for violating insider trading regulations. The violation pertains to non-compliance with pre-clearance requirements by a designated person within the company. Neuland Laboratories states that the issue is individual-specific and has no material impact on its financials or operations.

17May 25

Neuland Laboratories Stock Plunges 7% as Q4 Profit Nosedives 59%

Neuland Laboratories experienced a significant stock price decline of nearly 7% following disappointing Q4 FY2025 results. The company reported a 59% drop in profit after tax, with revenue decreasing by 13.99% year-over-year. Net profit fell by 58.88%, and EPS dropped from Rs 52.66 to Rs 21.67. The decline is attributed to increased operating costs and reduced sales volumes. Despite providing strong future guidance, investor caution persists, as reflected in the continued downward pressure on the stock price.

16May 25

Neuland Laboratories: Shares Drop 11% Despite FY26 Growth Assurance

Neuland Laboratories reported a 59% decrease in Q4 consolidated net profit to ₹278.10 crore, with revenue falling 15% to ₹328.00 crore. The company's shares dropped 11% following the weak results. Despite the downturn, Neuland expects growth to resume in FY26. Goldman Sachs maintains a 'Buy' rating with a ₹14,775.00 target price. The company announced a final dividend of ₹12.00 per equity share.

15May 25

Neuland Laboratories Reports Q4 Decline, Announces Dividend

Neuland Laboratories' Q4 results show a 13.68% year-over-year revenue decrease to ₹3.28 billion. Net profit fell 58.86% to ₹278.10 million, with EBITDA margin contracting to 15.55%. Despite the downturn, the company recommended a final dividend of ₹12.00 per equity share, subject to shareholder approval.